Ching Ching Leow

Ching Ching Leow has a strong background in pharmaceutical and biotech companies, with extensive experience in clinical development and translational medicine. They are currently serving as the VP, Head of Clinical for Loxo Oncology at Lilly, a position they have held since 2023. Prior to this role, they worked at Eli Lilly and Company, where they held various positions including Associate Vice President, VP Oncology Clinical Development and Portfolio Strategy, and VP Clinical Development IO. Before joining Eli Lilly and Company, Ching Ching Leow worked at AstraZeneca as a Medical Scientist and Translational Science Lead in the field of clinical oncology. They also have experience at MedImmune as a Scientist and at Genentech Inc. as a Post Doc. Ching Ching Leow began their career with a PhD from the University of Toronto.

Ching Ching Leow has a PhD in Molecular and Medical Genetics and Developmental Biology from the University of Toronto.